Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer

Yehui Shi(Tianjin Medical University Cancer Institute and Hospital), Hui Li(University of Maryland, Baltimore)
Cancer Immunology Immunotherapy
July 6, 2020
10.1007/s00262-020-02653-1
Cited by 71

Related Papers

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer
|Nature Medicine|2018|83
SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane
|Journal of Experimental & Clinical Cancer Research|2020|40
Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts
|Journal for ImmunoTherapy of Cancer|2025|13
HDAC6-Dependent Deacetylation of TAK1 Enhances sIL-6R Release to Promote Macrophage M2 Polarization in Colon Cancer
|Research Square|2022|0